- Title
- 1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH
- Creators
- A.R. Hansen - Princess Margaret Cancer CentreS. Probst - Jewish General HospitalR.F. Tutrone - Carolina Urologic Research CenterM.M. Osman - Saint Louis University HospitalE.S. Delpassand - Excel Diagnostics ImagingL.T. Nordquist - Urology Cancer Center and GU Research NetworkB.L. Viglianti - University of MichiganJ.M. Michalski - Washington University in St. LouisJ-M. Beauregard - Université LavalO.K. Oz - Southwestern Medical CenterK. Courtney - Southwestern Medical CenterJ. JensenW. WuN. Fleshner - Princess Margaret Cancer CentreO. Sartor - Tulane UniversityK.N. Chi - BC Cancer AgencyS.T. Tagawa - Cornell University
- Publication Details
- Annals of oncology, Vol.33, p.S1185
- Identifiers
- 991006262303902656
- Academic Unit
- Radiology
- Language
- English
- Resource Type
- Journal article
Journal article
1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH
Annals of oncology, Vol.33, p.S1185
09/2022
Metrics
1 Record Views